Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00605735 · ClinicalTrials.gov registry record · Phase 2
PoC in Rheumatoid Arthritis With Methotrexate
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT00605735 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 121 participants.
The verdict
NCT00605735, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if 300 mg of BMS-582949 given once daily will be more effective than placebo after 12 weeks of treatment in subjects with rheumatoid arthritis who are also taking methotrexate
Interventions
- DRUG Placebo
- DRUG BMS-582949
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00605735
The ClinicalTrials.gov registry entry for NCT00605735 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00605735 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00605735 about?
NCT00605735 is a clinical study titled "PoC in Rheumatoid Arthritis With Methotrexate". The purpose of this study is to find out if 300 mg of BMS-582949 given once daily will be more effective than placebo after 12 weeks of treatment in subjects with rheumatoid arthritis who are also taking methotrexate
What is the current status of trial NCT00605735?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2008-03. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00605735?
The interventions under investigation include: Placebo (DRUG), BMS-582949 (DRUG).
Who is sponsoring clinical trial NCT00605735?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.